Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer
Trial details
- Registry ID
- NCT02200757
- Phase
- Phase 2
The FDA approved Topotecan (Hycamtin) on 28 May 1996.
Drug identity checked against registry records
Also recorded as Hycamtin
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung CancerNCT02200757 | IBRX | Phase 2 | Completed | 2017-05-15Actual |
| REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1NCT05870748 | STRO | Phase 2, Phase 3 | Terminated | 2025-08-26Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 1996-05-28Day | Topotecan | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA020671", "applicant_as_listed_by_fda": "SANDOZ", "brand_names": ["HYCAMTIN"], "active_ingredients": ["TOPOTECAN HYDROCHLORIDE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "19960528", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |